Search This Blog

Friday, January 10, 2020

TELA Bio up premarket on revenue outlook

TELA Bio (NASDAQ:TELA) is up 5% premarket on announcing preliminary Q4 and FY 2019 revenue.
Q4 and FY 2019 revenue is expected in the range of $4.7M to $4.9M and $15.3M to $15.5M, respectively.
These strong results were driven by expansion of the commercial organization and introduction of larger sizes of OviTex during 2019.
The company will report its final Q4 and FY 2019 financial results during a conference call in March 2019.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.